الفهرس 
ch1Only 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Treatment of coronary ISR with DEB catheters is safe, effective and significantly reduced the incidence of restenosis. These data suggest that the inhibition of restenosis by local drug delivery may not require stent implantation and sustained drug release at the site of injury. The advantages of DCBs over standard angioplasty and stent technologies are
1-The potential for homogeneous drug delivery to the vessel wall, which is not, accomplished using DES.
2- Immediate drug release without the use of a polymer, which can induce chronic inflammation and late thrombosis as observed with some DES.
3- The option of using balloon catheters alone or in combination with a BMS.
4- No foreign object such as DES left behind in the body.
5- The potential of reducing antiplatelet therapy.
6- Lower restenosis rates in several coronary lesion types compared with conventional treatment.